Authors: Martha Powell, Future Science Group
The first trial of a vaccine to protect against SARS-CoV-2 has begun in the USA. Moderna (MA, USA) has announced that the first participants have been dosed in a Phase I trial of their experimental mRNA vaccine candidate, mRNA-1273.
The trial is being conducted by the National Institutes of Health (MD, USA) at Kaiser Permanente Washington Health Research Institute in Seattle (WA, USA). The team are aiming to recruit 45 healthy adults aged between 18 and 55 over a 6-week period to evaluate the safety of three mRNA-1273 doses. The participants will be given two intramuscular doses in total, 28 days apart, and will be followed for 12 months following the second dose.
The vaccine encodes a prefusion stabilised form of the coronavirus’ Spike (S) protein. The primary objective of the study Is to evaluate safety and reactogenicity on the two-dose schedule, but secondary outcomes will look at the immunogenicity to the SARS-CoV-2 S protein.
Moderna’s chief medical officer Tal Zaks commented: “This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2. We are actively preparing for a potential Phase II study.”
You might also like: